93 related articles for article (PubMed ID: 1551129)
21. Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.
Ask A; Persson L; Rehnholm A; Frostesjö L; Holm I; Heby O
Cancer Res; 1993 Nov; 53(21):5262-8. PubMed ID: 8221660
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis induced by inhibitors of nucleotide synthesis in deoxyadenosine-resistant leukemia L1210 cells that lack p53 expression.
Cory AH; Hickerson DH; Cory JG
Anticancer Res; 2000; 20(6B):4171-8. PubMed ID: 11205244
[TBL] [Abstract][Full Text] [Related]
23. Coexpression pattern of c-myc associated genes in a small cell lung cancer cell line with high steady state c-myc transcription.
Dooley S; Wundrack I; Blin N; Welter C
Biochem Biophys Res Commun; 1995 Aug; 213(3):789-95. PubMed ID: 7654239
[TBL] [Abstract][Full Text] [Related]
24. DMSO induced modulation of c-myc steady-state RNA levels in a variety of different cell lines.
Darling D; Tavassoli M; Linskens MH; Farzaneh F
Oncogene; 1989 Feb; 4(2):175-9. PubMed ID: 2648255
[TBL] [Abstract][Full Text] [Related]
25. [Activation of transcription of the tyrosine aminotransferase gene in the rat McA-RN 7777 hepatoma cell line by cycloheximide].
Kiseleva NP; Polotskaia AV; Adler VV
Mol Biol (Mosk); 1990; 24(5):1255-60. PubMed ID: 1981248
[TBL] [Abstract][Full Text] [Related]
26. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional up-regulation of gamma-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells.
Mulcahy RT; Untawale S; Gipp JJ
Mol Pharmacol; 1994 Nov; 46(5):909-14. PubMed ID: 7969079
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
Carter GL; Thompson DP; Cory JG
Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
[TBL] [Abstract][Full Text] [Related]
29. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Cory AH; Cory JG
Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998
[TBL] [Abstract][Full Text] [Related]
30. The expression of c-fos, c-jun, and c-myc genes is regulated by heat shock in human lymphoid cells.
Bukh A; Martinez-Valdez H; Freedman SJ; Freedman MH; Cohen A
J Immunol; 1990 Jun; 144(12):4835-40. PubMed ID: 2112575
[TBL] [Abstract][Full Text] [Related]
31. [Oncogene expression in adriamycin and platinum resistant cell lines].
Liu YB
Zhonghua Yi Xue Za Zhi; 1993 Sep; 73(9):552-4, 576. PubMed ID: 7906188
[TBL] [Abstract][Full Text] [Related]
32. Sequential protooncogene expression during rat liver regeneration.
Thompson NL; Mead JE; Braun L; Goyette M; Shank PR; Fausto N
Cancer Res; 1986 Jun; 46(6):3111-7. PubMed ID: 3516391
[TBL] [Abstract][Full Text] [Related]
33. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
34. Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells.
Spence MJ; Vestal RE; Liu J
Cancer Res; 1997 Jun; 57(11):2223-8. PubMed ID: 9187125
[TBL] [Abstract][Full Text] [Related]
35. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
36. Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle.
Skouv J; Jensen PO; Forchhammer J; Larsen JK; Lund LR
Cell Growth Differ; 1994 Mar; 5(3):329-40. PubMed ID: 8018565
[TBL] [Abstract][Full Text] [Related]
37. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
38. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
39. Interferon induced increases in c-myc expression in a human breast carcinoma cell line.
Hamburger AW; Pinnamaneni G
Anticancer Res; 1991; 11(5):1891-4. PubMed ID: 1768061
[TBL] [Abstract][Full Text] [Related]
40. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.
Davidoff AM; Pence JC; Shorter NA; Iglehart JD; Marks JR
Oncogene; 1992 Jan; 7(1):127-33. PubMed ID: 1741160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
